GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
11 Sep 2023 07:00 AM
RNS
Momelotinib filing accepted in Japan
06 Sep 2023 03:30 PM
RNS
Director/PDMR Shareholding
01 Sep 2023 03:00 PM
RNS
Total Voting Rights
01 Sep 2023 07:00 AM
RNS
GSK’s Nucala CRSwNP submission accepted in Japan
31 Aug 2023 03:16 PM
RNS
Holding(s) in Company
31 Aug 2023 03:14 PM
RNS
Holding(s) in Company
25 Aug 2023 03:30 PM
RNS
Director/PDMR Shareholding
23 Aug 2023 03:30 PM
RNS
Director/PDMR Shareholding
23 Aug 2023 07:00 AM
RNS
Shingrix data demonstrate 100% efficacy in China
22 Aug 2023 03:30 PM
RNS
Director/PDMR Shareholding
10 Aug 2023 03:30 PM
RNS
Director/PDMR Shareholding
09 Aug 2023 03:30 PM
RNS
Director/PDMR Shareholding
01 Aug 2023 03:00 PM
RNS
Total Voting Rights
31 Jul 2023 06:00 PM
RNS
FDA approves new use for Jemperli plus chemo
31 Jul 2023 03:30 PM
RNS
Director/PDMR Shareholding
28 Jul 2023 03:30 PM
RNS
Director/PDMR Shareholding
26 Jul 2023 07:00 AM
RNS
2nd Quarter Results
24 Jul 2023 07:00 AM
RNS
Cabotegravir LA for PrEP receives positive CHMP
20 Jul 2023 03:30 PM
RNS
Director/PDMR Shareholding
17 Jul 2023 03:30 PM
RNS
Director/PDMR Shareholding
13 Jul 2023 03:30 PM
RNS
Director/PDMR Shareholding
03 Jul 2023 03:00 PM
RNS
Total Voting Rights
28 Jun 2023 03:43 PM
RNS
GSK completes acquisition of BELLUS Health
27 Jun 2023 07:00 AM
RNS
FDA Fast Track for Gonorrhoea Vaccine Candidate
26 Jun 2023 07:05 AM
RNS
Shingrix approved in Japan for adults 18 and over
26 Jun 2023 07:00 AM
RNS
GSK daprodustat gains positive EMA CHMP opinion
23 Jun 2023 03:37 PM
RNS
Director/PDMR Shareholding
23 Jun 2023 03:33 PM
RNS
Director/PDMR Shareholding
23 Jun 2023 03:30 PM
RNS
Director/PDMR Shareholding
23 Jun 2023 07:00 AM
RNS
Statement: Zantac (ranitidine) litigation
22 Jun 2023 07:00 AM
RNS
GSK’s Arexvy recommended by ACIP
21 Jun 2023 07:00 AM
RNS
Season two data for GSK Arexvy RSV OA vaccine
16 Jun 2023 07:00 AM
RNS
Extension of FDA review period for momelotinib
12 Jun 2023 03:30 PM
RNS
Director/PDMR Shareholding
07 Jun 2023 07:00 AM
RNS
EU authorisation of GSK’s RSV vaccine Arexvy
06 Jun 2023 07:00 AM
RNS
GSK receives US FDA file acceptance for Jemperli
01 Jun 2023 03:00 PM
RNS
Total Voting Rights
22 May 2023 03:30 PM
RNS
Director/PDMR Shareholding
15 May 2023 03:30 PM
RNS
Director/PDMR Shareholding
15 May 2023 03:00 PM
RNS
Block listing Interim Review
12 May 2023 03:30 PM
RNS
Director/PDMR Shareholding
12 May 2023 09:50 AM
RNS
MenABCWY vaccine preliminary phase III results
12 May 2023 07:05 AM
RNS
Statement: Zantac Litigation Update BC Canada
12 May 2023 07:00 AM
RNS
GSK completes sale of shares in Haleon plc
11 May 2023 04:41 PM
RNS
GSK announces intention to sell shares in Haleon
09 May 2023 03:30 PM
RNS
Director/PDMR Shareholding
04 May 2023 03:30 PM
RNS
Director/PDMR Shareholding
03 May 2023 06:20 PM
RNS
Result of AGM
03 May 2023 06:00 PM
RNS
US FDA approves GSK’s RSV vaccine for older adults
03 May 2023 09:09 AM
RNS
Form 8.3 - Allergy Therapeutics plc

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

UK 100

Latest directors dealings